Skip to content

EBIT at other companies

10x Genomics, Inc. logo
10x Genomics, Inc.TXG
-$17.05M+56.7%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Danaher logo
DanaherDHR
TEC
Bio-TechneTECH
WAT
Waters CorporationWAT
Agilent Technologies logo
Agilent TechnologiesA

Other financials

Income statement

See full
Revenue$823.4M+2.7%
Gross profit$379.8M-2.9%
Operating income$10.2M-67.9%
Net income$14.4M-17.2%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$137.6M-26.7%
Total debt$1.7B-20.9%
Total equity$2.5B+34.6%
Total assets$6.1B+3.3%

Cash flow

See full
Operating cash flow$71.2M+9.5%
CapEx$24.2M-6.9%
Free cash flow$47.0M+20.5%

Valuation

See full
Market cap$8.71B-13.2%
Enterprise value$10.25B-14.9%
P/S2.5×-0.4×

Profitability

See full
Gross margin45.3%-3.7pp
Operating margin1.3%-5.0pp
Net margin-0.6%-10.0pp
FCF margin1.5%-3.6pp

Returns & leverage

See full
Return on equity-1%-21.2pp
Debt / equity0.7×-0.5×
Current ratio1.6×0.0×

Where this comes from

Calculated from Bruker’s reported figures.

Plus components not separately reported this period.

The official record: Bruker’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bruker's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bruker's EBIT?
Bruker (BRKR) reported EBIT of $10.2M in Q1 2026.
How has Bruker's EBIT changed year-over-year?
Bruker's EBIT decreased by 67.9% year-over-year, from $31.8M to $10.2M.
What is the long-term trend for Bruker's EBIT?
Over 4 years (2021 to 2025), Bruker's EBIT has grown at a -36.3% compound annual growth rate (CAGR), from $413.3M to $68.2M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.